Matches in SemOpenAlex for { <https://semopenalex.org/work/W81760983> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W81760983 endingPage "9" @default.
- W81760983 startingPage "204" @default.
- W81760983 abstract "The response to the different antimigraine medications is variable. In this study we have analysed the profile of prescription of these antimigraine medications, both preventive and symptomatic, by a group of spanish neurologists and examined the subjective efficacy of these compounds.Neurologists from 7 hospitals in different spanish regions interviewed 305 patients (at least 40 per hospital) who met migraine diagnostic criteria. They used an ad hoc questionnaire in which the antimigraine medications, both symptomatic and preventive, taken by the patients, as well as their subjective response were registered. Patients with transformed migraine or tension-type headache more than 2 days per week were excluded.Analgesics, non-steroidal anti-inflammatory drugs, ergotics and sumatriptan had been taken by 99, 69, 54 and 40% of the 305 interviewed patients, respectively. A subjective good response was refered to by 9% of patients who had taken analgesics, 23% of patients who had taken non-steroidal anti-inflammatory drugs, 39% of those who had taken ergotics and 63% of patients with sumatriptan. The current symptomatic treatment was: analgesics 34% of cases, non-steroidal anti-inflamatory drugs 26%, ergotics 13% and sumatriptan 63%. Regarding preventive treatments, 108 patients (35%) had been treated with calcium-antagonists, 87 (29%) with beta-blockers, 55 (18%) with amitriptyline and only 7 (2.2%) with valproic acid. The percentages of good responses to these drugs were: 55% for beta-blockers, 42% for calcium-antagonists and 31% for amitriptyline.Our data confirm that analgesics are not efficacious in the majority of migraine patients and that the advent of sumatriptan has clearly improved the quality of migrane symptomatic treatment, even though about one-third of migraine patients do not respond to this drug. This study confirm that calcium-antagonists are the antimigraine preventive treatment most frequently prescribed in our country, even though their subjective efficacy is lower than that of beta-blockers." @default.
- W81760983 created "2016-06-24" @default.
- W81760983 creator A5004481878 @default.
- W81760983 creator A5007839238 @default.
- W81760983 creator A5015773721 @default.
- W81760983 creator A5016986599 @default.
- W81760983 creator A5021632980 @default.
- W81760983 creator A5023959263 @default.
- W81760983 creator A5040917727 @default.
- W81760983 creator A5066942072 @default.
- W81760983 date "1999-05-01" @default.
- W81760983 modified "2023-10-17" @default.
- W81760983 title "[Spanish study of quality of life in migraine (II). Profile of medication consumption and subjective efficacy]." @default.
- W81760983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10377720" @default.
- W81760983 hasPublicationYear "1999" @default.
- W81760983 type Work @default.
- W81760983 sameAs 81760983 @default.
- W81760983 citedByCount "6" @default.
- W81760983 crossrefType "journal-article" @default.
- W81760983 hasAuthorship W81760983A5004481878 @default.
- W81760983 hasAuthorship W81760983A5007839238 @default.
- W81760983 hasAuthorship W81760983A5015773721 @default.
- W81760983 hasAuthorship W81760983A5016986599 @default.
- W81760983 hasAuthorship W81760983A5021632980 @default.
- W81760983 hasAuthorship W81760983A5023959263 @default.
- W81760983 hasAuthorship W81760983A5040917727 @default.
- W81760983 hasAuthorship W81760983A5066942072 @default.
- W81760983 hasConcept C118552586 @default.
- W81760983 hasConcept C126322002 @default.
- W81760983 hasConcept C170493617 @default.
- W81760983 hasConcept C2426938 @default.
- W81760983 hasConcept C2777172819 @default.
- W81760983 hasConcept C2778186239 @default.
- W81760983 hasConcept C2778541695 @default.
- W81760983 hasConcept C2778871607 @default.
- W81760983 hasConcept C2778938600 @default.
- W81760983 hasConcept C2780035454 @default.
- W81760983 hasConcept C2780216858 @default.
- W81760983 hasConcept C42219234 @default.
- W81760983 hasConcept C71924100 @default.
- W81760983 hasConcept C98274493 @default.
- W81760983 hasConceptScore W81760983C118552586 @default.
- W81760983 hasConceptScore W81760983C126322002 @default.
- W81760983 hasConceptScore W81760983C170493617 @default.
- W81760983 hasConceptScore W81760983C2426938 @default.
- W81760983 hasConceptScore W81760983C2777172819 @default.
- W81760983 hasConceptScore W81760983C2778186239 @default.
- W81760983 hasConceptScore W81760983C2778541695 @default.
- W81760983 hasConceptScore W81760983C2778871607 @default.
- W81760983 hasConceptScore W81760983C2778938600 @default.
- W81760983 hasConceptScore W81760983C2780035454 @default.
- W81760983 hasConceptScore W81760983C2780216858 @default.
- W81760983 hasConceptScore W81760983C42219234 @default.
- W81760983 hasConceptScore W81760983C71924100 @default.
- W81760983 hasConceptScore W81760983C98274493 @default.
- W81760983 hasIssue "5" @default.
- W81760983 hasLocation W817609831 @default.
- W81760983 hasOpenAccess W81760983 @default.
- W81760983 hasPrimaryLocation W817609831 @default.
- W81760983 hasRelatedWork W2004944265 @default.
- W81760983 hasRelatedWork W2020802469 @default.
- W81760983 hasRelatedWork W2077201042 @default.
- W81760983 hasRelatedWork W2129906084 @default.
- W81760983 hasRelatedWork W2131101452 @default.
- W81760983 hasRelatedWork W2385271979 @default.
- W81760983 hasRelatedWork W2396873391 @default.
- W81760983 hasRelatedWork W255674274 @default.
- W81760983 hasRelatedWork W2779205360 @default.
- W81760983 hasRelatedWork W81760983 @default.
- W81760983 hasVolume "14" @default.
- W81760983 isParatext "false" @default.
- W81760983 isRetracted "false" @default.
- W81760983 magId "81760983" @default.
- W81760983 workType "article" @default.